Biotech Catalysts to Watch: Key Opportunities Ahead

In 2026, four biotech catalysts stand out as significant investment opportunities. OTLK's ONS-5010, with a 65% approval probability, is a notable contender. With important dates on the horizon, investors should keep an eye on movements in the biotech catalyst calendar as we near crucial data releases and regulatory decisions.

The full biotech catalysts to watch

ONS-5010/LYTENAVA™: A Potential Breakthrough for nAMD

Outlook Therapeutics (OTLK) is pushing forward with ONS-5010/LYTENAVA™, a bevacizumab formulation targeting neovascular age-related macular degeneration (nAMD). This drug aims to offer an FDA-approved alternative to off-label options and fill a significant market gap. The global market for wet AMD could reach about $15 billion, highlighting the need for effective anti-VEGF therapies. Currently in the PDUFA phase, the FDA's decision is due by December 31, 2025. The clinical program includes two pivotal trials: NORSE ONE and NORSE TWO, with the latter focusing on a ≥15-letter improvement in best-corrected visual acuity (BCVA) at 11 months. Past results have been promising, yet the mixed efficacy from NORSE EIGHT remains a concern. The estimated approval probability is 65%, supported by a strong safety profile and the FDA's acceptance of the BLA. However, risks persist, particularly if further trials are needed due to NORSE EIGHT's endpoint failure. Investors should be ready for this crucial event, as a positive outcome could grant ONS-5010 12 years of marketing exclusivity.

Foralumab: Tiziana's Innovative MS Strategy

Tiziana Life Sciences (TLSA) is conducting a Phase 2a trial for intranasal foralumab, targeting non-active secondary progressive multiple sclerosis (na-SPMS). The drug's approval probability is around 20%, noteworthy given the challenges in treating na-SPMS, a condition that progresses without relapse. The trial has enrolled 17 of 54 patients, with top-line data expected in October 2026. Preliminary open-label data shows stabilization in Expanded Disability Status Scale (EDSS) scores and improved fatigue levels for all patients. However, the lack of pivotal efficacy readouts and absence of regulatory designations like Fast Track or Breakthrough Therapy are concerning. Risks are compounded by the low historical success rates for biologics in neurology, estimated at 15-25%. Foralumab's unique mechanism targeting microglial inflammation is promising, yet the small sample size and lack of direct comparator trials may hinder approval chances. Investors should watch the October data release closely, as it could significantly impact TLSA's path in the MS field.

CT-95: New Immunotherapy for Solid Tumors

Context Therapeutics (CNTX) is working on CT-95, a T cell engager bispecific antibody for solid tumors, now in Phase 1a trials. With an 18.5% approval probability, the drug faces significant risks typical of early-stage immunotherapy. The global market for MSLN-expressing solid tumors, such as pancreatic and ovarian cancers, is large, estimated at around $15 billion. CT-95's design aims to meet the unmet need in this area, though it hasn't received any regulatory designations, indicating its early development stage. Initial patient dosing began on June 28, 2026, with data expected mid-2026. Preclinical studies suggest a favorable safety profile, but the lack of efficacy data is worrying. Historical precedents in immunotherapy highlight the challenges of balancing efficacy and managing toxicity. Investors should focus on the upcoming data, as successful outcomes could position CT-95 as a leader in a demanding market.

NMRA-215: Preclinical Obesity Candidate

Neumora Therapeutics is developing NMRA-215, an oral brain-penetrant NLRP3 inhibitor for obesity, currently in preclinical stages. With a 4% approval probability, NMRA-215 faces a tough challenge in a crowded therapeutic area. Clinical trials are expected to start in the first quarter of 2026, with 12-week proof-of-concept data anticipated later that year. Preclinical studies show promising weight loss results in mice, but translating these findings to human efficacy is uncertain. The competitive landscape is dominated by established GLP-1/GIP therapies, making it difficult for NMRA-215 to stand out. The lack of regulatory designations and absence of human safety or efficacy data further complicate its outlook. Investors should be cautious, as the start of Phase 1 trials could provide critical insights into NMRA-215's potential.

The bottom line

Key dates for these biotech catalysts are approaching, so investors should stay vigilant and be ready to act on emerging data and regulatory outcomes.